SECTION 9 | Companion Diagnostics : From Enabler to Determinant of Long Term Leadership
Section Summary
Diagnostic sensitivity, not therapeutic mechanism, is emerging as one of the potential binding constraints on how many CEACAM5 patients can be treated. No CEACAM5 companion diagnostic is yet approved; existing assays remain in research-use-only (RUO), investigational, or laboratory-developed-test status. This section identifies the specific reagents and validation pathways — multiplex IHC, digital pathology, and whole-body imaging — that can expand the treatable population ahead of and alongside the first CEACAM5 approvals, applying AmethIntel’s Simultaneous Iterative Optimization (SIO™) methodology. These pathways are available to interested parties for collaboration.
Key Findings
→ The current flat IHC cutoff (Assay 769, ≥50% tumor cells at ≥2+) constrains the near-term treatable population to an estimated ~90,000 CEACAM5 positive patients annually — a subset of the report’s ~15% overall enrollment-eligible floor. See Section 1 for details
→ Multiplex IHC, buildable as a research-use assay within twelve months, is the nearest-term lever to expand that population toward estimated ~400,000 CEACAM5 patients annually, contributing to (Details of the numbers from Section 1, direction, not absolute numbers are critical).
→ Whole-body, non-invasive imaging (SGM-101, CEACAM5 PET nanobody/antibody constructs) is the superior long-term solution to the sampling bias inherent in any tissue-based assay.
→ Digital pathology standardization is the lowest-risk, highest-immediacy action, independent of how quickly multiplex or whole-body platforms mature.
→ White space in CEACAM5 diagnostics IP is concentrated in theranostics, multiplex/AI-augmented platforms, and longitudinal data assets — not in foundational antibody detection, where the field’s dominant reagents are largely public or expiring.
→ How improved diagnostics change trial-design and L1 strategy is examined in Section 3 and Section 10; the overarching leadership logic is in Section 2.